2 Jul 2015
Ergomed Strengthens Management Team & Board

Appoints Andrew Mackie to Lead Business Development

Guildford, UK – 2 July 2015: Ergomed plc, (LSE: ERGO or ‘Ergomed’) a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces the appointment of Andrew Mackie as Chief Business Officer and to its Board as Executive Director, effective from 1 July 2015.

Andrew brings with him over 25 years’ industry experience in pre-clinical research, clinical development and business development, having held at number of senior R&D roles in pharmaceutical (Lilly, Novartis, Sanofi), service (MDS), and biotech companies (Antisoma). He joins Ergomed from Eli Lilly where he was working for the Business Development team. Prior to this, Andrew was Head of Life Sciences at IP Group.

After ten years in R&D, Andrew joined the UK biotech sector in 1997 at Antisoma, the oncology specialist. He establish the clinical development department and transitioned new molecules into development and later managed Antisoma’s strategic alliance with F Hoffman-La Roche and in-licensed new drug leads through partnerships and acquisitions.

Rolf Stahel, Chairman of Ergomed commented: “I am very pleased to welcome Andrew to the Ergomed board. His expertise and experience will be invaluable as we continue to grow our services and co-development business and expand into new related areas.

Miroslav Reljanovic, Chief Executive Officer of Ergomed, said: “Over the past ten years, Andrew has worked with Ergomed as a consultant, and has been instrumental in developing the co-development business model, acting as lead negotiator on the partnerships signed to date. His successful track record in drug development and deal making not only strengthens our capabilities as we continue to advance our co-development pipeline but ensures we have the right team in place as we look to expand through organic growth and acquisitions.”

Andrew holds a BSc in biochemistry from Queen’s University (Canada), an LLB from the University of London and an MBA from the London Business School.

For further information, please contact:

Hume Brophy

Mary Clark, Supriya Mathur and Hollie Vile

Tel: + 44 203 440 5654

ergomed@humebrophy.com

 

Stifel Nicolaus Europe Limited

NOMAD/Broker to the Company

Jonathan Senior, Giles Balleny

Tel: + 44 207 710 7600

About Ergomed

Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.

Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.

Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.

As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: http://www.ergomedplc.com

Forward Looking Statements

Certain statements contained within the announcement are forward looking statements and are based on current expectations, estimates and projections about the potential returns of Ergomed plc (“Ergomed”) and industry and markets in which Ergomed operates, the Directors’ beliefs and assumptions made by the Directors. Words such as “expects”, “anticipates”, “should”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “pipeline” and variations of such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.

These forward-looking statements speak only as of the date of this announcement. Ergomed expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in Ergomed’s expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.